Table 1 Patient and disease characteristics at baseline in the safety analysis set and full analysis set
Characteristic | Safety analysis set N = 38 | Full analysis set N = 37 |
|---|---|---|
Sex | ||
Male | 15 (39.5) | 15 (40.5) |
Female | 23 (60.5) | 22 (59.5) |
Age, years | ||
Median (range) | 77.5 (75–91) | 77.0 (75–91) |
Weight, kg | ||
Median (range) | 50.2 (30.8–72.2) | 50.5 (30.8–72.2) |
BMI, kg/m2 | ||
Median (range) | 21.0 (16.5–26.0) | 21.2 (16.5–26.0) |
Smoking status | ||
Never | 26 (68.4) | 25 (67.6) |
Former/current | 12 (31.6) | 12 (32.4) |
ECOG PS | ||
0 | 21 (55.3) | 20 (54.1) |
1 | 17 (44.7) | 17 (45.9) |
Histological classification | ||
Adenocarcinoma | 38 (100) | 37 (100) |
Clinical stage at study entry | ||
IIIB | 1 (2.6) | 1 (2.7) |
IV | 28 (73.7) | 28 (75.7) |
Postoperative recurrence | 9 (23.7) | 8 (21.6) |
Comorbidities | ||
Yes | 32 (84.2) | 31 (83.8) |
No | 6 (15.8) | 6 (16.2) |
Metastases at study entry | ||
No distant metastases | 4 (10.5) | 4 (10.8) |
Lung | 10 (26.3) | 10 (27.0) |
Bone | 13 (34.2) | 13 (35.1) |
Post palliative RT | 1 (2.6) | 1 (2.7) |
Brain | 13 (34.2) | 13 (35.1) |
Post palliative SRS | 3 (7.9) | 3 (8.1) |
Liver | 4 (10.5) | 4 (10.8) |
Pleural | 11 (28.9) | 11 (29.7) |
EGFR mutation categories | ||
Del19 | 23 (60.5) | 22 (59.5) |
L858R | 15 (39.5) | 15 (40.5) |